Skip to main content
. Author manuscript; available in PMC: 2015 Aug 11.
Published in final edited form as: J Clin Exp Oncol. 2013;2(2):1000109.

Figure 3.

Figure 3

Detection of total anti-HER2/neu immunoglobulin in the form of gemcitabine-(C4-amide)-[anti-HER2/neu] bound to the exterior surface membrane of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunochemotherapeutic was incubated with monolayer populations of mammary adenocarcinoma (SKBr-3) over a 4-hour period and total immunoglobulin bound to the exterior surface membrane was measured by cell-ELISA.